Sonoma Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SNOA)

$4.51 -0.15 (-3.22 %)
(As of 12/13/2017 03:58 AM ET)
Previous Close$4.66
Today's Range$4.47 - $4.63
52-Week Range$4.16 - $8.25
Volume25,800 shs
Average Volume30,222 shs
Market Capitalization$20.15 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2

About Sonoma Pharmaceuticals (NASDAQ:SNOA)

Sonoma Pharmaceuticals logoSonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company's product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid. Microcyn is a small-molecule oxychlorine compound with antimicrobial and anti-inflammatory properties that, in clinical settings, reduces itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue. Lipogrid Technology contains selected lipids and a lipid precursor designed to penetrate the bilayers of the skin by blending with the natural lipid building blocks. Its products serve over five million patients across the globe by reducing infections, itch, pain, scarring and inflammatory responses. Its products are sold throughout the United States and internationally.

Receive SNOA News and Ratings via Email

Sign-up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:SNOA
CUSIPN/A
Phone+1-707-2830550

Debt

Debt-to-Equity Ratio0.01%
Current Ratio5.37%
Quick Ratio4.56%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.82 million
Price / Sales1.55
Cash FlowN/A
Price / CashN/A
Book Value$5.00 per share
Price / Book0.90

Profitability

Trailing EPS($1.99)
Net Income$9.27 million
Net Margins47.68%
Return on Equity-43.23%
Return on Assets-35.78%

Miscellaneous

Employees243
Outstanding Shares4,400,000

Sonoma Pharmaceuticals (NASDAQ:SNOA) Frequently Asked Questions

What is Sonoma Pharmaceuticals' stock symbol?

Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNOA."

How were Sonoma Pharmaceuticals' earnings last quarter?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.82) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.73) by $0.09. The business had revenue of $3.84 million for the quarter. Sonoma Pharmaceuticals had a net margin of 47.68% and a negative return on equity of 43.23%. View Sonoma Pharmaceuticals' Earnings History.

Where is Sonoma Pharmaceuticals' stock going? Where will Sonoma Pharmaceuticals' stock price be in 2017?

1 brokers have issued 1-year price objectives for Sonoma Pharmaceuticals' stock. Their forecasts range from $11.00 to $11.00. On average, they expect Sonoma Pharmaceuticals' stock price to reach $11.00 in the next year. View Analyst Ratings for Sonoma Pharmaceuticals.

Who are some of Sonoma Pharmaceuticals' key competitors?

Who are Sonoma Pharmaceuticals' key executives?

Sonoma Pharmaceuticals' management team includes the folowing people:

  • James J. Schutz, President, Chief Executive Officer, Director (Age 53)
  • Robert Allen Northey Ph.D., Executive Vice President - Research and Development (Age 59)
  • Bruce Thornton, Executive Vice President - International Operations and Sales (Age 52)
  • Marc Umscheid, Chief Strategy and Marketing Officer
  • Robert Miller, Chief Financial Officer, Chief Operating Officer, Secretary (Age 73)
  • Jerry G. McLaughlin, Lead Independent Director (Age 68)
  • Sharon A. Barbari, Independent Director (Age 62)
  • Jay E. Birnbaum Ph.D., Independent Director (Age 71)
  • Russell Harrison, Independent Director (Age 71)

How do I buy Sonoma Pharmaceuticals stock?

Shares of Sonoma Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sonoma Pharmaceuticals' stock price today?

One share of Sonoma Pharmaceuticals stock can currently be purchased for approximately $4.51.

How big of a company is Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals has a market capitalization of $20.15 million and generates $12.82 million in revenue each year. The company earns $9.27 million in net income (profit) each year or ($1.99) on an earnings per share basis. Sonoma Pharmaceuticals employs 243 workers across the globe.

How can I contact Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals' mailing address is 1129 N Mcdowell Blvd, PETALUMA, CA 94954-1110, United States. The company can be reached via phone at +1-707-2830550 or via email at [email protected]


MarketBeat Community Rating for Sonoma Pharmaceuticals (SNOA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  199
MarketBeat's community ratings are surveys of what our community members think about Sonoma Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sonoma Pharmaceuticals (NASDAQ:SNOA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.00$11.00$10.00$10.00
Price Target Upside: 120.44% upside134.55% upside46.63% upside29.03% upside

Sonoma Pharmaceuticals (NASDAQ:SNOA) Consensus Price Target History

Price Target History for Sonoma Pharmaceuticals (NASDAQ:SNOA)

Sonoma Pharmaceuticals (NASDAQ:SNOA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2017Maxim GroupSet Price TargetBuy$11.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Sonoma Pharmaceuticals (NASDAQ:SNOA) Earnings History and Estimates Chart

Earnings by Quarter for Sonoma Pharmaceuticals (NASDAQ:SNOA)

Sonoma Pharmaceuticals (NASDAQ SNOA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q1 2018($0.73)($0.82)$3.84 millionViewListenView Earnings Details
6/5/2017Q4 2017($0.67)($0.69)$4.03 millionViewListenView Earnings Details
2/9/2017Q3 2017$3.08$3.84$3.36 millionViewListenView Earnings Details
6/16/2016Q4($0.16)$3.53 millionViewListenView Earnings Details
2/4/2016Q216($0.07)($0.19)$3.56 million$3.80 millionViewListenView Earnings Details
7/30/2015Q116($0.10)($0.15)$3.96 million$3.70 millionViewListenView Earnings Details
6/11/2015Q215($0.25)($0.11)$3.12 million$3.98 millionViewListenView Earnings Details
2/12/2015Q115($0.18)($0.69)$3.10 million$3.22 millionViewListenView Earnings Details
8/7/2014Q1 15($0.17)($0.01)$3.13 million$3.39 millionViewN/AView Earnings Details
6/12/2014Q4 14($0.21)$0.99$3.42 million$2.91 millionViewN/AView Earnings Details
11/19/2013Q2($0.15)($0.21)$4.03 million$4.10 millionViewListenView Earnings Details
8/8/2013Q1 2014($0.26)($0.26)$3.68 million$3.37 millionViewN/AView Earnings Details
2/13/2013Q3 2013($0.08)($0.05)$3.28 million$3.50 millionViewN/AView Earnings Details
11/1/2012Q312$0.03($0.05)$5.59 million$4.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Sonoma Pharmaceuticals (NASDAQ:SNOA) Earnings Estimates

Current Year EPS Consensus Estimate: $-3 EPS
Next Year EPS Consensus Estimate: $-2.3 EPS

Dividends

Dividend History for Sonoma Pharmaceuticals (NASDAQ:SNOA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Sonoma Pharmaceuticals (NASDAQ SNOA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 9.39%
Insider Trades by Quarter for Sonoma Pharmaceuticals (NASDAQ:SNOA)
Institutional Ownership by Quarter for Sonoma Pharmaceuticals (NASDAQ:SNOA)

Sonoma Pharmaceuticals (NASDAQ SNOA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/29/2017James J SchutzCEOBuy400$5.03$2,012.00View SEC Filing  
11/29/2017Robert E MillerCFOBuy1,790$5.02$8,985.80View SEC Filing  
11/24/2017James J SchutzCEOBuy254$5.05$1,282.70View SEC Filing  
11/21/2017Robert E MillerCFOBuy2,000$5.03$10,060.00View SEC Filing  
8/10/2017James J SchutzCEOBuy929$5.46$5,072.34View SEC Filing  
8/10/2017Marc UmscheidInsiderBuy600$5.31$3,186.00View SEC Filing  
8/10/2017Robert E MillerCFOBuy2,264$5.30$11,999.20View SEC Filing  
3/9/2017Robert E MillerCFOBuy750$7.02$5,265.00View SEC Filing  
3/8/2017Robert E MillerCFOBuy1,000$6.93$6,930.00View SEC Filing  
3/6/2017Marc UmscheidInsiderBuy750$6.82$5,115.00View SEC Filing  
3/3/2017James J SchutzCEOBuy800$6.78$5,424.00View SEC Filing  
12/8/2016James J SchutzCEOBuy1,000$4.88$4,880.00View SEC Filing  
12/8/2016Robert E MillerCFOBuy5,000$4.86$24,300.00View SEC Filing  
8/15/2016James J SchutzCEOBuy1,328$3.66$4,860.48View SEC Filing  
2/25/2016James J SchutzCEOBuy5,000$1.00$5,000.00View SEC Filing  
11/17/2014James J SchutzCEOBuy6,285$1.78$11,187.30View SEC Filing  
8/16/2013James SchutzCEOBuy5,100$2.35$11,985.00View SEC Filing  
12/10/2012Hojabr AlimiCEOBuy5,500$0.64$3,520.00View SEC Filing  
12/7/2012Hojabr AlimiCEOBuy5,300$0.65$3,445.00View SEC Filing  
11/9/2012James J SchutzCOOBuy13,000$0.80$10,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sonoma Pharmaceuticals (NASDAQ SNOA) News Headlines

Source:
DateHeadline
Comparing 3SBio (SSRX) & Sonoma Pharmaceuticals (SNOA)Comparing 3SBio (SSRX) & Sonoma Pharmaceuticals (SNOA)
www.americanbankingnews.com - December 10 at 11:34 PM
Does Sonoma Pharmaceuticals Inc’s (SNOA) Recent Track Record Look Strong?Does Sonoma Pharmaceuticals Inc’s (SNOA) Recent Track Record Look Strong?
finance.yahoo.com - November 30 at 11:21 AM
Sonoma Pharmaceuticals, Inc. (SNOA) CFO Robert E. Miller Buys 2,000 SharesSonoma Pharmaceuticals, Inc. (SNOA) CFO Robert E. Miller Buys 2,000 Shares
www.americanbankingnews.com - November 24 at 4:48 PM
Sonoma Pharmaceuticals, Inc. (SNOA) Given a $11.00 Price Target at Maxim GroupSonoma Pharmaceuticals, Inc. (SNOA) Given a $11.00 Price Target at Maxim Group
www.americanbankingnews.com - November 17 at 3:54 PM
Sonoma Pharmaceuticals (SNOA) Expanded Indication for Alevicyn Approved by FDASonoma Pharmaceuticals (SNOA) Expanded Indication for Alevicyn Approved by FDA
www.streetinsider.com - November 17 at 1:55 PM
Sonoma Pharmaceuticals (SNOA) Expanded Indication for Alevicyn Approved by FDA - StreetInsider.comSonoma Pharmaceuticals (SNOA) Expanded Indication for Alevicyn Approved by FDA - StreetInsider.com
www.streetinsider.com - November 16 at 8:37 AM
Sonoma Pharmaceuticals Announces FDA Approval of Expanded Indication for Alevicyn™ to Add Antimicrobial LanguageSonoma Pharmaceuticals Announces FDA Approval of Expanded Indication for Alevicyn™ to Add Antimicrobial Language
finance.yahoo.com - November 16 at 8:37 AM
What You Must Know About Sonoma Pharmaceuticals Inc’s (SNOA) Financial StrengthWhat You Must Know About Sonoma Pharmaceuticals Inc’s (SNOA) Financial Strength
finance.yahoo.com - November 15 at 10:05 AM
Sonoma Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call SlidesSonoma Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides
seekingalpha.com - November 12 at 2:51 AM
Sonoma Pharmaceuticals (SNOA) CEO Jim Schutz on Q2 2018 Results - Earnings Call Transcript - Seeking AlphaSonoma Pharmaceuticals' (SNOA) CEO Jim Schutz on Q2 2018 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 11 at 1:51 PM
Sonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue ... - GlobeNewswire (press release)Sonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue ... - GlobeNewswire (press release)
globenewswire.com - November 10 at 11:26 AM
Sonoma Pharmaceuticals (SNOA) PT Raised to $11 at Maxim Group - StreetInsider.comSonoma Pharmaceuticals (SNOA) PT Raised to $11 at Maxim Group - StreetInsider.com
www.streetinsider.com - November 10 at 11:26 AM
Sonoma Pharmaceuticals (SNOA) "Buy" Rating Reaffirmed at Maxim GroupSonoma Pharmaceuticals' (SNOA) "Buy" Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - November 10 at 11:24 AM
Sonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue Growth and Total Revenue of $4.3 MillionSonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue Growth and Total Revenue of $4.3 Million
finance.yahoo.com - November 9 at 6:50 PM
Sonoma Pharmaceuticals, Inc. to Host Earnings CallSonoma Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 1:45 PM
Sonoma Pharmaceuticals Receives Brazilian Approvals to Market Multiple Hypochlorous Acid-Based Dermatology ProductsSonoma Pharmaceuticals Receives Brazilian Approvals to Market Multiple Hypochlorous Acid-Based Dermatology Products
finance.yahoo.com - October 31 at 9:47 AM
Sonoma Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results and Conference Call - GlobeNewswire (press release)Sonoma Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results and Conference Call - GlobeNewswire (press release)
globenewswire.com - October 28 at 6:24 AM
Sonoma Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results and Conference CallSonoma Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results and Conference Call
finance.yahoo.com - October 28 at 6:24 AM
ETFs with exposure to Sonoma Pharmaceuticals, Inc. : October 25, 2017ETFs with exposure to Sonoma Pharmaceuticals, Inc. : October 25, 2017
finance.yahoo.com - October 25 at 10:53 AM
Sonoma Pharmaceuticals (SNOA) and VIVUS (VVUS) Head-To-Head ContrastSonoma Pharmaceuticals (SNOA) and VIVUS (VVUS) Head-To-Head Contrast
www.americanbankingnews.com - October 18 at 2:24 PM
Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA)Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA)
finance.yahoo.com - October 18 at 8:46 AM
Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA)Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA)
finance.yahoo.com - October 18 at 8:46 AM
Sonoma Pharmaceuticals Announces U.S. Commercialization of Loyon® for Relief of Scaling, Burning and Itching Associated with Various Dermatoses Including Seborrhea and Seborrheic DermatitisSonoma Pharmaceuticals Announces U.S. Commercialization of Loyon® for Relief of Scaling, Burning and Itching Associated with Various Dermatoses Including Seborrhea and Seborrheic Dermatitis
finance.yahoo.com - October 3 at 12:38 PM
Critical Review: Sonoma Pharmaceuticals (SNOA) vs. Its PeersCritical Review: Sonoma Pharmaceuticals (SNOA) vs. Its Peers
www.americanbankingnews.com - September 27 at 6:22 AM
Head to Head Contrast: Sonoma Pharmaceuticals (SNOA) and Its RivalsHead to Head Contrast: Sonoma Pharmaceuticals (SNOA) and Its Rivals
www.americanbankingnews.com - September 22 at 2:16 PM
Contrasting Sonoma Pharmaceuticals (SNOA) and Its RivalsContrasting Sonoma Pharmaceuticals (SNOA) and Its Rivals
www.americanbankingnews.com - September 21 at 4:28 AM
Sonoma Pharmaceuticals (SNOA) Reports Commercialization of ... - StreetInsider.comSonoma Pharmaceuticals (SNOA) Reports Commercialization of ... - StreetInsider.com
www.streetinsider.com - September 15 at 9:09 AM
Sonoma Pharmaceuticals Announces Commercialization of ... - GlobeNewswire (press release)Sonoma Pharmaceuticals Announces Commercialization of ... - GlobeNewswire (press release)
globenewswire.com - September 14 at 10:19 AM
ETFs with exposure to Sonoma Pharmaceuticals, Inc. : September 14, 2017ETFs with exposure to Sonoma Pharmaceuticals, Inc. : September 14, 2017
finance.yahoo.com - September 14 at 10:18 AM
Sonoma Pharmaceuticals Announces Commercialization of MicrocynAH® Animal Healthcare Products in JapanSonoma Pharmaceuticals Announces Commercialization of MicrocynAH® Animal Healthcare Products in Japan
finance.yahoo.com - September 14 at 10:18 AM
Analyzing Sonoma Pharmaceuticals (SNOA) and its CompetitorsAnalyzing Sonoma Pharmaceuticals (SNOA) and its Competitors
www.americanbankingnews.com - September 11 at 6:24 PM
Financial Contrast: Sonoma Pharmaceuticals (SNOA) and Tokai Pharmaceuticals (NVUS)Financial Contrast: Sonoma Pharmaceuticals (SNOA) and Tokai Pharmaceuticals (NVUS)
www.americanbankingnews.com - September 6 at 6:26 PM
ETFs with exposure to Sonoma Pharmaceuticals, Inc. : September 1, 2017ETFs with exposure to Sonoma Pharmaceuticals, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 8:56 AM
ETFs with exposure to Sonoma Pharmaceuticals, Inc. : September 1, 2017ETFs with exposure to Sonoma Pharmaceuticals, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 8:56 AM
Sonoma Pharmaceuticals, Inc. :SNOA-US: Earnings Analysis: Q1, 2018 By the Numbers : August 25, 2017Sonoma Pharmaceuticals, Inc. :SNOA-US: Earnings Analysis: Q1, 2018 By the Numbers : August 25, 2017
finance.yahoo.com - August 25 at 4:20 PM
Sonoma Pharmaceuticals (SNOA) CEO Jim Schutz on Fiscal Q1 2018 Results - Earnings Call Transcript - Seeking AlphaSonoma Pharmaceuticals' (SNOA) CEO Jim Schutz on Fiscal Q1 2018 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 15 at 7:07 AM
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) CFO Robert E. Miller Buys 2,264 SharesSonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) CFO Robert E. Miller Buys 2,264 Shares
www.americanbankingnews.com - August 15 at 12:16 AM
Sonoma Pharmaceuticals, Inc. (SNOA) Announces  Earnings ResultsSonoma Pharmaceuticals, Inc. (SNOA) Announces Earnings Results
www.americanbankingnews.com - August 10 at 6:12 PM
Sonoma Pharmaceuticals Reports Financial Results for First Quarter ... - NasdaqSonoma Pharmaceuticals Reports Financial Results for First Quarter ... - Nasdaq
www.nasdaq.com - August 9 at 7:36 AM
Sonoma Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018Sonoma Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018
finance.yahoo.com - August 9 at 7:36 AM
Sonoma Pharmaceuticals Announces Fiscal First Quarter 2018 Financial Results and Conference Call - GlobeNewswire (press release)Sonoma Pharmaceuticals Announces Fiscal First Quarter 2018 Financial Results and Conference Call - GlobeNewswire (press release)
globenewswire.com - July 26 at 8:09 AM
CORRECTING and REPLACING -- Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data - GlobeNewswire (press release)CORRECTING and REPLACING -- Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data - GlobeNewswire (press release)
globenewswire.com - July 14 at 8:33 AM
CORRECTING and REPLACING -- Sonoma Pharmaceuticals Announces Record Quarterly Prescription DataCORRECTING and REPLACING -- Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data
finance.yahoo.com - July 14 at 8:33 AM
Sonoma Pharmaceuticals announces record quarterly prescription data - Seeking AlphaSonoma Pharmaceuticals announces record quarterly prescription data - Seeking Alpha
seekingalpha.com - July 13 at 9:40 AM
Sonoma Pharmaceuticals Announces Record Quarterly Prescription DataSonoma Pharmaceuticals Announces Record Quarterly Prescription Data
finance.yahoo.com - July 13 at 9:40 AM
ETFs with exposure to Sonoma Pharmaceuticals, Inc. : July 11, 2017ETFs with exposure to Sonoma Pharmaceuticals, Inc. : July 11, 2017
finance.yahoo.com - July 11 at 3:26 PM
Sonoma Pharmaceuticals, Inc. :SNOA-US: Earnings Analysis: Q4, 2017 By the Numbers : July 10, 2017Sonoma Pharmaceuticals, Inc. :SNOA-US: Earnings Analysis: Q4, 2017 By the Numbers : July 10, 2017
finance.yahoo.com - July 11 at 7:49 AM
Sonoma Pharmaceuticals Inc (SNOA) Files 10-K for the Fiscal Year Ended on March 31, 2017 - NasdaqSonoma Pharmaceuticals Inc (SNOA) Files 10-K for the Fiscal Year Ended on March 31, 2017 - Nasdaq
www.nasdaq.com - June 30 at 6:49 AM
Sonoma Pharmaceuticals (SNOA) Reports Publication of Consensus Report Describing Celacyns (Hypochlorous Acid ... - StreetInsider.comSonoma Pharmaceuticals (SNOA) Reports Publication of Consensus Report Describing Celacyn's (Hypochlorous Acid ... - StreetInsider.com
www.streetinsider.com - June 28 at 8:02 AM
Sonoma Pharmaceuticals Announces Two Singapore Approvals for Microcyn® (hypochlorous acid) for the Treatment ... - GlobeNewswire (press release)Sonoma Pharmaceuticals Announces Two Singapore Approvals for Microcyn® (hypochlorous acid) for the Treatment ... - GlobeNewswire (press release)
globenewswire.com - June 22 at 6:41 PM

SEC Filings

Sonoma Pharmaceuticals (NASDAQ:SNOA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sonoma Pharmaceuticals (NASDAQ:SNOA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sonoma Pharmaceuticals (NASDAQ SNOA) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.